These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 26021206)
1. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. Kaz AM; Grady WM; Stachler MD; Bass AJ Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206 [TBL] [Abstract][Full Text] [Related]
2. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus. Grady WM; Yu M Dig Dis Sci; 2018 Aug; 63(8):2059-2069. PubMed ID: 29766388 [TBL] [Abstract][Full Text] [Related]
3. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291 [TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717 [TBL] [Abstract][Full Text] [Related]
5. The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression. Ramzan Z; Nassri AB; Huerta S Expert Rev Mol Diagn; 2014 Jun; 14(5):575-91. PubMed ID: 24831686 [TBL] [Abstract][Full Text] [Related]
6. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316 [TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175 [TBL] [Abstract][Full Text] [Related]
8. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence]. Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680 [TBL] [Abstract][Full Text] [Related]
9. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570 [TBL] [Abstract][Full Text] [Related]
10. The diagnosis and management of Barrett's esophagus. DeMeester SR; DeMeester TR Adv Surg; 1999; 33():29-68. PubMed ID: 10572561 [TBL] [Abstract][Full Text] [Related]
11. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. Whitson MJ; Falk GW Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196 [TBL] [Abstract][Full Text] [Related]
12. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585 [TBL] [Abstract][Full Text] [Related]
13. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963 [TBL] [Abstract][Full Text] [Related]
14. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431 [TBL] [Abstract][Full Text] [Related]
15. Progression to cancer in Barrett's esophagus is associated with genomic instability. Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184 [TBL] [Abstract][Full Text] [Related]
16. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622 [TBL] [Abstract][Full Text] [Related]
17. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340 [TBL] [Abstract][Full Text] [Related]